Latest News in Pharma industry
U.S. vs. Germany: The Biotech Trade War Upending Global Pharma Prices
GSK Acquires Nuvalent for $10.6B: A Strategic Bet on Lung Cancer Dominance
The GLP-1 Pill War: Eli Lilly’s Foundayo Triumph vs. Novo Nordisk’s Market Moat
RVMD Stock: The $30B Valuation Trap Behind Daraxonrasib's Pancreatic Cancer Breakthrough
Regeneron's Carefully Staged Day: Science, Politics, and the Cash-Flow Reality Behind the Headlines
Amazon Moves Into Weight-Loss Care—But the Real Play Is Channel Capture
Eli Lilly Bets $7 Billion on a Needle That Reprograms Cancer Cells Inside the Body
Kailera's $2 Billion Debut: A Hot IPO in a Cooling Obesity Trade
OpenAI Plants a Vertical Flag in Biology — And the Timing Tells the Real Story
Novo Nordisk Hands OpenAI the Keys to Its Operating Engine
Lilly's Jaypirca Clears a Real Hurdle in CLL — but the Victory Lap Is Premature
FDA's $7.2B Budget Signals a Pharma Regime Change
Neurocrine's $2.9B Soleno Deal: Paying a Premium Price for a One-Asset Rare-Disease Bet
Lilly’s Foundayo Gets FDA Green Light in 50 Days — The Pill That Could Industrialize Obesity Treatment
Takeda's $1.3B Reset: What the Layoffs Really Signals
Aleniglipron Phase 2 Results: Is Structure Therapeutics (GPCR) the Next Big Obesity Drug Stock?
Novo Nordisk’s $2.1 Billion Vivtex Deal Could Reshape Oral Obesity and Diabetes Drugs
Pfizer Buys Speed, Not Control: The $495M China Obesity Bet Explained
Novo Nordisk's CagriSema Fails to Match Lilly's Tirzepatide — And the Real Damage Is Deeper Than the Headline
Novartis Sells India Crown Jewel for Pocket Change — The Real Story Is What It's Buying Instead
BRINSUPRI's Explosive Launch: Can Insmed Turn a $145M Quarter Into a $1 Billion Blockbuster in 2026?
J&J's $1 Billion Pennsylvania Factory: The Cell Therapy Manufacturing Play Investors Are Missing
Danaher-Masimo: The $9.9B Deal That Rewrites Medtech's Power Map
Novartis's Kidney Drug Just Missed a Critical Trial Threshold — and the FDA Fight Is Just Beginning
Sanofi Pulls the Emergency Brake: What the Hudson Ouster and Garijo Appointment Really Mean for Investors
Has AI Finally Solved Drug Design? Isomorphic Labs Says Its New Engine Beats AlphaFold 3 and Physics-Based Methods
Novo Nordisk's $50 Billion Reckoning: When Legal Victory over Hims & Hers May Spell Strategic Defeat
Merck Beats the Quarter. The Business Beneath the Beat Is a Different Story.
FDA Tells AstraZeneca to Come Back With More Data Before It Can Approve a Self-Injection Version of Its Lupus Drug
Lilly's $1.12 Billion Hearing Loss Bet: Platform Optionality Over Near-Term Returns
GSK Pays $2 Billion for RAPT's Experimental Food Allergy Drug Two Years Before Trial Results
Lilly Wins Fast Track for Ovarian Cancer Drug, But the Real Battle Lies Ahead
Novavax-Pfizer Deal Exposes the Real Bet: Can Validation Become Revenue?
Boston Scientific's $14.5 Billion Bet: Why the Penumbra Deal Is About Survival, Not Just Growth
The $1 Billion Question Mark: Inside Ipsen's High-Stakes Bet on Leukemia's Most Treacherous Territory
FDA Shadow Looms as Travere Shares Plunge Hours Before Kidney Drug Verdict
GSK Says New Hepatitis B Treatment Works But Won't Reveal How Many Patients It Cured
Lilly's Billion-Dollar Bet on Inflammation: Why the Ventyx Deal Is About 2030, Not Tomorrow
Novo Nordisk's $149 Obesity Pill Marks End of Weight-Loss Drug Premium Era
Ultragenyx Collapses 41% as Bone Drug Exposes Fundamental Limits of Density-Based Therapy
The $1.5 Billion Reckoning: How a Single Talc Verdict Exposes Johnson & Johnson's Grinding Legal Reality
Sanofi Doubles Down on B-Cell Depletion Hours After MS Drug Flops
FDA Probes Vaccine Deaths as Politics Reshapes American Medicine
America's Pharma Shakedown: How Trump Forced Britain to Subsidize Drug Companies
Novartis Bets $23 Billion on American Manufacturing—And It's Not About Innovation
Arrowhead Just Won FDA Approval, But the Math Tells a Different Story
J&J's $3 Billion Halda Bet: A Calculated Wager on Cancer's Most Stubborn Problem
Novo Nordisk's Foundation Just Staged a Corporate Coup—and Investors Aren't Happy
Merck's $9.2 Billion Cidara Bet Reveals Big Pharma's New Math on Viral Prevention
Game-Changing MS Pill Could Redefine Treatment: Genentech’s Fenebrutinib Sparks New Hope for Millions
Load More